All In Biotech

Drug Trial Radar · NCT07778667

A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease

A Multicenter, Open-label, Single-arm, Baseline-controlled Trial to Assess the Efficacy and Safety of Lucerastat in Treatment-naïve/Pseudo-naïve Adult Male Participants With Fabry Disease

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Feb 13, 2029

Study completion Mar 15, 2029

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn how well lucerastat works and how safe it is in untreated adult male participants with Fabry disease. The main question this clinical trial aims to answer is: • Does treatment with lucerastat affects the amount of globotriaosylceramide (Gb3), a fatty substance that builds up in the kidneys, in untreated adult men with Fabry disease? This is an open-label, single-arm trial, which means that participants will know which trial medication they receive and only one trial medication will be given. Trial participants will: * Take lucerastat every day for 18 months * Have kidney biopsies at the end and start of the trial * Visit the clinic 10 times for check-up and tests * Take part in the trial for up to 21 months in total

Conditions

  • Fabry Disease

Interventions

  • LucerastatDrug

    Hard gelatine capsules of 250 mg lucerastat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to Month 18 in kidney Gb3 BLISS score (average number of Gb3 inclusions per kidney peritubular capillary (PTC)).Time frame: Baseline and Month 18

Locations

16 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama of Birmingham

    Birmingham, Alabama · Not yet recruiting

  • UCSF Benioff Childens Hospital

    Oakland, California · Not yet recruiting

  • UF Health Center for Pediatric Neuromuscular and Rare Diseases

    Gainesville, Florida · Not yet recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Not yet recruiting

  • Ann & Robert H. Lurie Childrens Hospital of Chicago

    Chicago, Illinois · Not yet recruiting

  • The University of Minnesota, Fairview Health

    Minneapolis, Minnesota · Not yet recruiting

  • Hospital of University Pennsylvania, Translational Medicine and Human Genetics

    Philadelphia, Pennsylvania · Not yet recruiting

  • Dallas Nephrology Associates (DNA) - Dallas Landry Office Practice

    Dallas, Texas · Recruiting

  • VG Site pharmacy Dept 6 N-279

    Halifax, Nova Scotia, Canada · Not yet recruiting

  • CIUSSS-NIM/Hopital du sacre-Coeur de MontrealUnite de Recherche, Local C2030

    Montreal, Quebec, Canada · Not yet recruiting

  • Hôpital Raymond-Poincaré

    Garches, Île-de-France Region, France · Not yet recruiting

  • Centre Hospitalier Universitaire de Toulouse -Hôpital Purpan

    Toulouse, Midi-Pyrénées, France · Not yet recruiting

  • Universitaetsklinikum Wuerzburg AöR

    Grombuehl, Bavaria, Germany · Not yet recruiting

  • Charite Universitaetsmedizin Berlin KöR

    Mitte, State of Berlin, Germany · Not yet recruiting

  • The Royal Free London NHS Foundation Trust - The Royal Free

    London, City of London, United Kingdom · Not yet recruiting

  • Salford Royal NHS Foundation Trust part of the Northern Care

    Salford, Lancashire, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.